Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 14/20 | 0.68 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 17/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 11/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20013439 | 1.00 | P2RY6 (0.68) | P2RY6NT5EP2RY2P2RY4 | |
| SCHEMBL21665258 | 0.98 | P2RY6 (0.66) | P2RY6NT5EP2RY2P2RY4 | |
| SCHEMBL20013415 | 0.98 | P2RY6 (0.66) | P2RY6NT5EP2RY2P2RY4 | |
| SCHEMBL20013771 | 0.93 | P2RY6 (0.58) | P2RY6NT5EP2RY2P2RY4 | |
| SCHEMBL20013630 | 0.93 | P2RY6 (0.58) | P2RY6NT5EP2RY2P2RY4 | |
| SCHEMBL20013434 | 0.93 | P2RY6 (0.58) | P2RY6NT5EP2RY2P2RY4 | |
| SCHEMBL21450027 | 0.92 | P2RY6 (0.76) | P2RY6NT5EP2RY2P2RY4 | |
| SCHEMBL15279691 | 0.92 | P2RY6 (0.76) | P2RY6NT5EP2RY2P2RY4 | |
| SCHEMBL19308867 | 0.92 | P2RY6 (0.76) | P2RY6NT5EP2RY2P2RY4 | |
| SCHEMBL15276355 | 0.92 | P2RY6 (0.76) | P2RY6NT5EP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200040025-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040025-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | P2RY6 1/4885NT5E 51/4885P2RY2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.